These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33538559)

  • 1. Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With Impetigo.
    Schachner LA; Andriessen A; Benjamin LT; Claro C; Eichenfield LF; Esposito SM; Keller L; Kircik L; Kwong PC; McCuaig C
    J Drugs Dermatol; 2021 Feb; 20(2):134-142. PubMed ID: 33538559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Ozenoxacin Cream 1% for Impetigo: A Review.
    Schachner L; Andriessen A; Bhatia N; Grada A; Patele D
    J Drugs Dermatol; 2019 Jul; 18(7):655-661. PubMed ID: 31334625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Impetigo and Antimicrobial Resistance.
    Schachner LA; Lynde CW; Kircik LH; Torrelo A; Hohl D; Kwong P; Oza V; Andriessen A; Hebert AA
    J Drugs Dermatol; 2021 Apr; 20(4):366-372. PubMed ID: 33852242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of ozenoxacin in animal models of dermal infection with Staphylococcus aureus.
    Tarragó C; Esquirol LP; Arañó A; Lachamp L; D'Aniello F; Zsolt I
    Future Microbiol; 2018 May; 13():21-30. PubMed ID: 29745240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current options for the treatment of impetigo in children.
    Sladden MJ; Johnston GA
    Expert Opin Pharmacother; 2005 Oct; 6(13):2245-56. PubMed ID: 16218885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
    Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
    J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ozenoxacin: a review of preclinical and clinical efficacy.
    Vila J; Hebert AA; Torrelo A; López Y; Tato M; García-Castillo M; Cantón R
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):159-168. PubMed ID: 30686133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.
    Canton R; Morrissey I; Vila J; Tato M; García-Castillo M; López Y; Gargallo-Viola D; Zsolt I
    Future Microbiol; 2018 May; 13():3-19. PubMed ID: 29745242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the antibacterial activity of ozenoxacin.
    Canton R; Chouinard L; Tarragó C
    Future Microbiol; 2018 May; 13():1-2. PubMed ID: 29745241
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnosis and management of impetigo.
    VanRavenstein K; Durham CO; Williams TH; Smith W
    Nurse Pract; 2017 Mar; 42(3):40-44. PubMed ID: 28178083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.
    Rosen T; Albareda N; Rosenberg N; Alonso FG; Roth S; Zsolt I; Hebert AA
    JAMA Dermatol; 2018 Jul; 154(7):806-813. PubMed ID: 29898217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.
    Gropper S; Albareda N; Chelius K; Kruger D; Mitha I; Vahed Y; Gani M; García-Alonso F;
    Future Microbiol; 2014; 9(9):1013-23. PubMed ID: 25340832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiological profile of a new topical antibacterial: retapamulin ointment 1%.
    Scangarella-Oman NE; Shawar RM; Bouchillon S; Hoban D
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):269-79. PubMed ID: 19344241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin.
    Woodford N; Afzal-Shah M; Warner M; Livermore DM
    J Antimicrob Chemother; 2008 Oct; 62(4):766-8. PubMed ID: 18567573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Impetigo in the Pediatric Population: Consensus and Future Directions.
    Schachner LA; Torrelo A; Grada A; Micali G; Kwong PC; Scott GB; Benjamin L; Gonzalez ME; Andriessen A; Eberlein T; Eichenfield LF
    J Drugs Dermatol; 2020 Mar; 19(3):281-290. PubMed ID: 32550690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retapamulin (Altabax)--a new topical antibiotic.
    Med Lett Drugs Ther; 2008 Feb; 50(1280):13-5. PubMed ID: 18292714
    [No Abstract]   [Full Text] [Related]  

  • 17. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study.
    Oranje AP; Chosidow O; Sacchidanand S; Todd G; Singh K; Scangarella N; Shawar R; Twynholm M;
    Dermatology; 2007; 215(4):331-40. PubMed ID: 17911992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ozenoxacin 1% cream (Xepi) for impetigo.
    Med Lett Drugs Ther; 2019 Apr; 61(1570):63-64. PubMed ID: 31169810
    [No Abstract]   [Full Text] [Related]  

  • 19. Retapamulin: a newer topical antibiotic.
    Dhingra D; Parakh A; Ramachandran S
    J Postgrad Med; 2013; 59(2):127-30. PubMed ID: 23793314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus.
    Weinberg JM; Tyring SK
    J Drugs Dermatol; 2010 Oct; 9(10):1198-204. PubMed ID: 20941943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.